Announcements Trials

Browse Landscape

Phase

Status

Recruiting 34 Active not recruiting 24 Not yet recruiting 3 Completed 3 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

pembrolizumab 29 Carboplatin 15 Cisplatin 13 Nivolumab 12 atezolizumab 10 Radiotherapy 10 Paclitaxel 10 Ipilimumab 10 venetoclax 9 Pemetrexed 9 Docetaxel 9 durvalumab 8 Gemcitabine 8 fludarabine 7 Specimen Handling 7 Cyclophosphamide 7 Bevacizumab 7 tislelizumab 6 fludarabine phosphate 6 Trastuzumab 6 Practice Guidelines as Topic 6 Cetuximab 6 Biopsy 6 enzalutamide 5 Surveys and Questionnaires 5 Standard of Care 5 Radiosurgery 5 Magnetic Resonance Spectroscopy 5 Dexamethasone 5 Cytarabine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × obinutuzumab × 90 days × Clear all

NCT05896163 2026-05-06

MAPtivate-6

Pfizer

Phase 1/2 Terminated

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡